• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Naresh Nunna by Naresh Nunna
54 minutes ago
in Science News
0
Illustration of budding fungal cells and the same cells turning into branching threads

Researchers at CSIR-CCMB in Hyderabad report that two pyruvate kinase inhibitors prevent Candida albicans from switching into its invasive filamentous form. (Illustration)

Researchers at the CSIR Centre for Cellular and Molecular Biology in Hyderabad, working with the Translational Health Science and Technology Institute, have identified two small molecules that prevent Candida albicans from switching into the thread-like form it uses to invade tissue — without killing the fungus. The compounds target glycolysis, the cell’s sugar-processing pathway, and specifically the enzyme pyruvate kinase. In laboratory work they cut biofilm formation by roughly three-quarters, made the fungus more vulnerable to two standard antifungals, and improved survival in infected mice. The approach matters because killing a pathogen selects for resistance, and merely disarming it may not.

Candida albicans lives harmlessly in the gut, mouth and on the skin of a large fraction of healthy people. It becomes dangerous when it changes shape. In its yeast form it is a round, budding single cell. Under certain conditions it elongates into filaments — hyphae and pseudohyphae — that penetrate tissue, form drug-resistant mats called biofilms on catheters and implants, and allow the organism to spread into the bloodstream. Invasive candidiasis is lethal in a substantial proportion of cases, and the World Health Organization has placed C. albicans in the critical-priority group of its fungal pathogen list.

The number of antifungal drug classes available to clinicians is very small — far smaller than the antibacterial armoury — and resistance to them is rising. That scarcity is why a different kind of target is interesting.

What the Hyderabad group did

The work comes from the laboratory of Dr Sriram Varahan at CSIR-CCMB, with collaborators at BRIC-THSTI, the Translational Health Science and Technology Institute in Faridabad. The first author is Dhrumi Shah, with affiliations given as CCMB, the Academy of Scientific and Innovative Research and THSTI.

The group’s starting point was metabolic rather than pharmacological. The switch from yeast to filament is an expensive change for a cell to make, and the team’s premise was that glycolysis — the pathway that breaks down glucose to pyruvate and supplies both energy and carbon skeletons — functions as the gate controlling it. If glycolysis is the gate, then inhibiting a glycolytic enzyme should hold the fungus in its harmless round form.

They screened 112 compounds known to target glycolytic enzymes. Two emerged: NPD10084 and PKM2-IN-6, both inhibitors of pyruvate kinase, the enzyme that catalyses the final step of glycolysis.

The reported results, taken from the group’s preprint, are:

  • Both compounds blocked the yeast-to-filament switch.
  • Biofilm formation was reduced by about 77 per cent.
  • One compound increased the fungus’s sensitivity to fluconazole and amphotericin B, the two mainstays of antifungal therapy.
  • Treatment improved survival in mice with systemic infection.

Why anti-virulence is a different strategy

Conventional antimicrobials kill, and killing imposes the strongest possible selection pressure: any variant that survives inherits the whole population. This is the mechanism by which resistance emerges, and it operates on antifungals exactly as it does on antibiotics.

An anti-virulence compound works differently in principle. If a molecule does not kill the fungus but only prevents it from adopting its invasive form, the selective advantage conferred by resistance to that molecule is weaker, because a non-resistant organism is not eliminated — it simply remains commensal. The theoretical consequence is slower evolution of resistance.

NSH notes that this is an argument from principle, widely discussed in the field, and not something this study demonstrates. No resistance-evolution experiment is reported. The claim that anti-virulence approaches generate resistance more slowly remains a hypothesis in need of its own evidence.

The second reported finding is arguably the more immediately useful one. If blocking pyruvate kinase makes C. albicans more susceptible to fluconazole and amphotericin B, then the compounds could function as adjuvants — given alongside existing antifungals to make lower doses effective, or to restore the effectiveness of a drug the strain has become partially resistant to. Adjuvant strategies have a clearer route to the clinic than wholly new agents, because the partner drug is already approved.

What is not yet established

Three limitations are substantial, and NSH states them rather than burying them.

First, the journal citation cannot be confirmed. News reports describe the work as published in ACS Infectious Diseases. NSH searched the publisher’s site, PubMed and PubMed Central, including by exact title, and could not locate the paper, a DOI or a publication date. The compound names, mechanism and effect sizes reported above are therefore taken from the group’s bioRxiv preprint, which NSH read, and not from a peer-reviewed version of record. NSH flags that the preprint exists in two versions which differ on one set of findings. Readers and editors should treat the figures as preprint figures until the journal record appears.

Second, this is preclinical work. The mouse survival experiment used six animals, which is a small group even by the standards of early animal studies, and the evidence that the compounds bind pyruvate kinase at the proposed site is computational modelling rather than structural biology. Neither compound is an approved medicine, and neither has been through toxicology in humans.

Third, inhibiting a core metabolic enzyme raises an obvious safety question. Pyruvate kinase is not a fungus-specific enzyme; human cells run glycolysis too, and PKM2 is a human pyruvate kinase isoform that has been studied extensively as a cancer target. Whether a compound can inhibit the fungal enzyme sufficiently without disturbing host metabolism is precisely the question that preclinical development exists to answer, and it is unanswered here.

The context in which it lands

The work was reported as World AMR Awareness Week opened on 18 November, under the WHO theme “One Health, one action: Prevent AMR now”, and in the same window as the Indian Council of Medical Research’s surveillance report documenting severe resistance in Indian hospitals — including the finding that Candida species are among the commonest organisms in bloodstream infections in newborns.

That juxtaposition is the reason this item deserves attention beyond its novelty. India has a documented, measured problem with resistant hospital-acquired infection, including fungal infection in its most vulnerable patients, and the research response is coming from Indian public laboratories. CCMB is a CSIR institute; THSTI is a Department of Biotechnology institute. This is publicly funded Indian science working on a problem Indian hospitals are measuring.

The distance from a screened compound to a usable drug remains long — typically a decade or more, with high attrition — and most compounds that look promising at this stage do not arrive. That is the normal shape of drug discovery and not a criticism of the work.

– Rashmi M

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: AntimicrobialResistanceCandidaCCMBCSIRDrugDiscoveryHealthSciencesHyderabadLifeSciences
Naresh Nunna

Naresh Nunna

Other Posts

Technicians in cleanroom suits at a wafer-handling station

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

November 21, 2026
0
Everyday plastic containers, a cosmetic bottle and a feeding bottle in a row

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

November 21, 2026
0

The Morning Eye Closes: NASA Will Switch Off Terra After 27 Years of Watching the Planet

A Status Lost: Measles Is Endemic Again in the United States, Mexico and Bolivia

The Earthshot Comes to Mumbai: An Indian Electric Three-Wheeler Maker Wins £1 Million for Cleaner City Air

Robots Now Outrun Humans. What Does That Prove?

The People Behind the “Autonomous” Robot

Where Humanoid Robots Actually Work Today

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
9

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist